Core Viewpoint - The report from CMB International raises the target price for Sihuan Pharmaceutical (01530) to HKD 39.5, maintaining a "Buy" rating and highlighting it as a key industry recommendation [1] Group 1: Clinical Data and Development - Strong clinical data, unwavering support from partners, and extensive R&D experience have increased confidence in the global development success of the 707 project [1] - The overseas development of the 707 project is progressing rapidly [1] Group 2: Business Spin-off - Sihuan Pharmaceutical plans to spin off its consumer pharmaceutical business, Mandi International, for a listing in Hong Kong, through a distribution of shares and a global offering of new shares [1] - After the spin-off, Sihuan Pharmaceutical will no longer hold any equity in Mandi International, which currently holds 87.16% [1] - The spin-off is expected to bring short-term investment returns and allow the company to focus on prescription and innovative drugs, with the raised funds supporting the commercialization of self-developed innovative products [1]
交银国际：维持三生制药(01530)“买入”评级 目标价上调至39.5港元